Included in the formulation
АТХ:N.05.C Sleeping and sedatives
Pharmacodynamics:Reversibly binds neuropeptides of wakefulness. Block orexin receptors OX1R and OX2R, located in the hypothalamus and affecting the process of wakefulness, as a result of which suppresses the wakefulness regime.
Pharmacokinetics:After ingestion, up to 82% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 2 hours. The connection with plasma proteins is 99%.
Metabolism in the liver.
The half-life is 12 hours. Elimination with feces and kidneys.
Indications:It is used to treat insomnia.
VI.G40-G47.G47.0 Disturbances of falling asleep and maintaining sleep [insomnia]
Contraindications:Severe respiratory and hepatic insufficiency, a symptom of sleep apnea, depression, myasthenia gravis, age to 18 years, pregnancy and lactation, individual intolerance.
Carefully:Bronchoectatic disease, the presence of sleep apnea, alcohol and drug dependence, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inside, for 10-15-20 mg for 1 hour before sleep.
The highest daily dose: 20 mg.
The highest single dose: 20 mg.
Side effects:Central and peripheral nervous system: drowsiness, headache, weakness, drowsiness, euphoria, anterograde amnesia, signs of latent depression, paradoxical reactions: excitement, aggression, hallucinations, nightmarish dreams, suicidal tendencies.
Respiratory system: cough, dyspnea, upper respiratory tract infections, hyperventilation.
Digestive system: dyspepsia, dry mouth,
Musculoskeletal system: decrease in muscle tone of the lower limbs.
Allergic reactions.
Overdose:Drowsiness, confusion, lethargy, ataxia, breathing disorders, coma.
Treatment is symptomatic.
Interaction:Strengthens the sedative effect of ethanol, antipsychotic drugs, hypnotics, antihistamines and narcotic analgesics.
Cimetidine increases the concentration of suvorexant in the blood by 85%.
Ketoconazole and erythromycin increase the sedative effect of suvorexant.
Rifampicin, carbamazepine, phenobarbital derivatives reduce the effectiveness of suvorexant by 25%.
Simultaneous use with opioid analgesics causes euphoria and forms a psychicaddiction.
Special instructions:It is not recommended to take ethanol during treatment with suvorecant.
Given the side effect of suicidal tendencies, it is not recommended to increase the dose of more than 20 mg per day.
When taking the drug is not recommended driving and working with moving machinery.